Parkinson's drug tested for eye disease

NCT ID NCT03197493

First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This study tests a drug called carbidopa-levodopa (Sinemet), typically used for Parkinson's disease, in people with wet age-related macular degeneration (AMD). It is a 9-month extension for 35 participants who completed an earlier study. The goal is to see if the drug can help maintain vision and reduce retinal swelling.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

carbidopa-levodopa (Sinemet)

What this could lead to

If it works, this could point toward a new oral treatment to help control vision loss in wet age-related macular degeneration.

What could go wrong

This is a small, early-phase extension study with only 35 participants. It may not show clear benefits, and the drug can cause side effects like nausea or dizziness.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NEOVASCULAR AGE-RELATED MACULAR DEGENERATION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

macular degeneration wet macular degeneration

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Robert W Snyder, MD, PhD, PC

    Tucson, Arizona, 85712, United States